Type1 Diabetes Mellitus
Conditions
Keywords
Type 1 Diabetes Mellitus, Empagliflozin, Artificial Pancreas, SGLT2 inhibitor, insulin pump, closed loop
Brief summary
The most advanced configurations of the Artificial Pancreas (AP) have not yet been demonstrated to sufficiently maximize time in target glycemia. One limitation is the challenge of postprandial glycemic control, which currently requires ongoing patient engagement for accurate and detailed bolus dose estimation for meals. Sodium Glucose Linked Transporter 2 Inhibition (SGLT2i) provides an additional mechanism to attenuate post-prandial glycemic excursion, and may represent a strategy that could further alleviate carbohydrate counting burden and improve the performance of AP configurations. This trial aims to compare - using a randomized, masked placebo-controlled, crossover, multicenter design - the efficacy of the SGLT2i empagliflozin 25 mg oral per day each in the setting of single-hormone automated AP and conventional insulin pump therapy on the proportion of time spent in target and in hypoglycemia each during a 4-week day-and-night period. The pilot trial aims to enroll 28 adult patients with type 1 diabetes (T1D) across 2 research sites (one in Toronto and one in Montreal) and includes a 2- week therapy optimization run-in period, 4-weeks for each of the two AP intervention arms, and a 1- week washout in between the pharmacological intervention sequences. Glucose levels will be measured by continuous glucose monitoring (G5, Dexcom Inc.). Insulin will be infused using a subcutaneous infusion pump (t-slim, Tandem Diabetes Care) and communication between pumps and the algorithm will be implemented using Android Smartphone devices and Bluetooth technology communication.
Interventions
DRUGempagliflozin
Treatment with empagliflozin 25mg orally once a day
DEVICEartificial pancreas
Insulin delivery via a closed loop single-hormone artificial pancreas system.
Sponsors
McGill University Health Centre/Research Institute of the McGill University Health Centre
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed and dated written informed consent by the date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation. 2. Males and females ≥ 18 years of age. 3. Clinical diagnosis of T1D for at least one year. The diagnosis of T1D is based on the investigator's clinical judgment; C peptide level and antibody determinations are not planned. 4. Insulin pump therapy use for at least 3 months. 5. HbA1c ≤ 10%. 6. eGFR ≥ 60 mL/min/1.73 m² as calculated by the CKD-EPI formula. 7. Women of child-bearing potential must be ready and able to use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly.
Exclusion criteria
1. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. 2. Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. Renal insufficiency (characterized at eGFR below 60 mmol/l at the beginning of the trial) 4. History of pheochromocytoma or insulinoma 5. Beta-blockers at high dose (interference with glucose management). 6. Chronic acetaminophen treatment (can interfere with glucose sensor measurements). 7. Warfarin chronic treatment if INR monitoring cannot be evaluated (can increase the risk of bleeding). 8. Current use of other non-insulin adjunct anti-hyperglycemic drug or use within 30 days prior to screening. 9. Use of loop diuretics (e.g. furosemide, due to possible interference with study drug mechanism of action). 10. Ongoing or planned pregnancy or breastfeeding. 11. Severe hypoglycemic episode within one month prior to Visit 1. 12. Diabetic ketoacidosis in the last 3 months prior to Visit 1. 13. Current use of glucocorticoid medication except low stable dose and inhaled steroids (can interfere with glucose sensor measurements). 14. Known or suspected allergy to the trial products. 15. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. 16. Anticipating a significant change in exercise regimen between initiation of two intervention blocks (i.e. starting or stopping an organized sport). 17. Recent history of genital or urinary infection (\<1 month prior to Visit 1) or history of recurrent urinary tract infections. 18. Difficulty in using the artificial pancreas system following training.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks AP on empagliflozin and 4-weeks AP with placebo | 20 weeks | Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks AP on empagliflozin and 4-weeks AP with placebo. |
| Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4- weeks conventional pump therapy with placebo | 20 weeks | Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4- weeks conventional pump therapy with placebo. |
| Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy on empagliflozin | 20 weeks | Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy on empagliflozin. |
| Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy with placebo | 20 weeks | Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy with placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absolute number of hypoglycemia events I. | 20 weeks | Number of hypoglycemic events (\> 20 minutes) below 3.3 mmol/L based on sensor glucose levels |
| Absolute number of hypoglycemia events II. | 20 weeks | Number of symptomatic hypoglycemic events \< 3.9 mmol/l or below 3.3 mmol/l without symptoms |
| Absolute number of hypoglycemia events III. | 20 weeks | Number of treated hypoglycemic events |
| Statistical characteristics of glucose profile I. | 20 weeks | Area under the curve of hypoglycemic glucose values (below 3.9 mmol/L, 3.3 mmol/L and 2.8 mmol/L) |
| Statistical characteristics of glucose profile II. | 20 weeks | Standard deviation of glucose levels |
| Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4-weeks AP on empagliflozin | 20 weeks | Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4-weeks AP on empagliflozin |
| Change in HbA1c | 20 weeks | Change in HbA1c from baseline to after the first intervention and from the end of the first intervention to the end of the treatment period. |
| Mean fasting capillary ketone levels | 20 weeks | Mean fasting capillary ketone levels. |
| Number of episodes of diabetic ketoacidosis | 20 weeks | Number of episodes of diabetic ketoacidosis |
| Number of technical adverse events | 20 weeks | Number of events when algorithm crashes or needs to be overridden for safety reasons. |
| Amount of total insulin delivery during interventions | 20 weeks | Total insulin delivery measured by mean of units per day |
| Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks AP on empagliflozin and 4- weeks AP with placebo | 20 weeks | Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks AP on empagliflozin and 4- weeks AP with placebo. |
| Hypoglycemia: Percentage of time with glucose <3.9 mmol/L applied to each of the primary and secondary outcome comparator groups | 20 weeks | Hypoglycemia: Percentage of time with glucose \<3.9 mmol/L applied to each of the primary and secondary outcome comparator groups. |
| Percentage of time spent in hypoglycemia, euglycemia and hyperglycemia | 20 weeks | Percentage of time spent in the different glucose sensor levels characterized by amount spent between 3.9 and 10.0 mmol/L, 3.9 and 7.8 mmol/L, above 10.0 mmol/L, above 13.9 mmol/L, above 16.7 mmol/l, below 3.9 mmol/L, below 3.3 mmol/L, below 2.8 mmol/L |
Countries
Canada
Outcome results
None listed